Salem Investment Counselors’s GSK GSK Stock Holding History

Salem Investment Counselors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$124K	Sell	2,348 -8	-0.3%	-$423	﹤0.01%	470
2026 Q1	$131K	Buy	+2,356	New	+$128K	﹤0.01%	439
2025 Q4	–	Sell	-2,348	Closed	-$102K	–	697
2025 Q3	$102K	Hold	2,348	–	–	﹤0.01%	464
2025 Q2	$91.2K	Hold	2,348	–	–	﹤0.01%	470
2025 Q1	$91.9K	Buy	2,348 +500	+27%	+$18.3K	﹤0.01%	468
2024 Q4	$63.2K	Sell	1,848 -20	-1%	-$720	﹤0.01%	537
2024 Q3	$77.1K	Sell	1,868 -140	-7%	-$5.73K	﹤0.01%	497
2024 Q2	$78.1K	Hold	2,008	–	–	﹤0.01%	481
2024 Q1	$86.9K	Buy	2,008 +80	+4%	+$3.3K	﹤0.01%	470
2023 Q4	$72.1K	Buy	1,928 +40	+2%	+$1.44K	﹤0.01%	489
2023 Q3	$69.1K	Hold	1,888	–	–	﹤0.01%	474
2023 Q2	$68K	Hold	1,888	–	–	﹤0.01%	482
2023 Q1	$67.8K	Sell	1,888 -300	-14%	-$10.5K	﹤0.01%	481
2022 Q4	$78.6K	Sell	2,188 -2,818	-56%	-$93.9K	﹤0.01%	450
2022 Q3	$149K	Sell	5,006 -233	-4%	-$8.83K	0.01%	345
2022 Q2	$287K	Buy	5,239 +533	+11%	+$29.4K	0.01%	292
2022 Q1	$256K	Hold	4,706	–	–	0.01%	310
2021 Q4	$259K	Sell	4,706 -160	-3%	-$8.32K	0.01%	338
2021 Q3	$232K	Buy	4,866 +160	+3%	+$8.04K	0.01%	325
2021 Q2	$234K	Hold	4,706	–	–	0.01%	306
2021 Q1	$210K	Hold	4,706	–	–	0.01%	277
2020 Q4	$216K	Sell	4,706 -80	-2%	-$3.67K	0.01%	272
2020 Q3	$225K	Buy	4,786 +160	+3%	+$8.02K	0.02%	240
2020 Q2	$236K	Hold	4,626	–	–	0.02%	227
2020 Q1	$219K	Hold	4,626	–	–	0.02%	223
2019 Q4	$272K	Hold	4,626	–	–	0.02%	226
2019 Q3	$247K	Hold	4,626	–	–	0.02%	230
2019 Q2	$231K	Sell	4,626 -240	-5%	-$12K	0.02%	239
2019 Q1	$244K	Buy	4,866 +240	+5%	+$12K	0.02%	182
2018 Q4	$221K	Sell	4,626 -240	-5%	-$11.8K	0.03%	177
2018 Q3	$244K	Hold	4,866	–	–	0.02%	182
2018 Q2	$245K	Hold	4,866	–	–	0.02%	184
2018 Q1	$237K	Sell	4,866 -76	-2%	-$3.54K	0.03%	183
2017 Q4	$219K	Buy	4,942 +76	+2%	+$3.51K	0.02%	188
2017 Q3	$249K	Hold	4,866	–	–	0.03%	186
2017 Q2	$262K	Hold	4,866	–	–	0.03%	193
2017 Q1	$255K	Sell	4,866 -508	-9%	-$25.8K	0.03%	222
2016 Q4	$259K	Buy	+5,374	New	+$265K	0.03%	221
2016 Q3	–	Sell	-4,877	Closed	-$264K	–	532
2016 Q2	$264K	Hold	4,877	–	–	0.03%	223
2016 Q1	$247K	Hold	4,877	–	–	0.03%	225
2015 Q4	$246K	Hold	4,877	–	–	0.03%	227
2015 Q3	$232K	Hold	4,877	–	–	0.03%	239
2015 Q2	$254K	Hold	4,877	–	–	0.03%	244
2015 Q1	$281K	Hold	4,877	–	–	0.03%	242
2014 Q4	$261K	Sell	4,877 -1,120	-19%	-$62.7K	0.03%	237
2014 Q3	$345K	Hold	5,997	–	–	0.04%	223
2014 Q2	$401K	Sell	5,997 -16,320	-73%	-$1.1M	0.05%	213
2014 Q1	$1.49M	Hold	22,317	–	–	0.18%	118
2013 Q4	$1.49M	Hold	22,317	–	–	0.19%	112
2013 Q3	$1.4M	Sell	22,317 -3,520	-14%	-$227K	0.19%	112
2013 Q2	$1.61M	Buy	+25,837	New	+$1.64M	0.23%	94

Other funds holding GSK

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.82B AUM

ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

FVWA

Foster Victor Wealth Advisors Greenville, South Carolina $1.9B AUM 24.46% 1-Year Est. Return

SIS

Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

KFP

Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return

Salem Investment Counselors's GSK Position: Q2 2026 in Review

Salem Investment Counselors reduced its GSK (GSK) stake by 0.34% in Q2 2026, selling an estimated $423 and leaving 2,348 shares worth $124K. The position accounts for ﹤0.01% of the portfolio, ranked #470.

Salem Investment Counselors first reported a position in GSK in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.61M in Q2 2013. 399 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Salem Investment Counselors held 2,348 shares of GSK worth $124K as of Q2 2026.
Salem Investment Counselors sold 8 GSK shares in Q2 2026, an estimated $423.
GSK made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #470 holding.
Salem Investment Counselors first reported a position in GSK in Q2 2013 and has held it in 51 quarters since.
Salem Investment Counselors's GSK position peaked at $1.61M in Q2 2013.
399 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.